Lim Kin Sheng, García-Feijóo Julián, Klabe Karsten
KCL Frost Eye Research Department, St Thomas' Hospital, London, UK.
Hospital Clinico San Carlos, Instituto de Investigaciones Oftalmologicas Ramon Castroviejo, Universidad Complutense de Madrid, Madrid, Spain.
Graefes Arch Clin Exp Ophthalmol. 2025 May 8. doi: 10.1007/s00417-025-06843-4.
Subconjunctival bleb-forming devices (SBD) can provide greater intraocular pressure reductions than minimally invasive glaucoma surgery (MIGS) whilst remaining less invasive than traditional surgical techniques. However, variations in management practices and surgical techniques indicate the need for concise and clear guidance on these procedures in diverse patient populations. Here we describe current recommendations on the use of PRESERFLO MicroShunt, an ab externo SBD, according to a review of current literature and the opinions of 20 international glaucoma experts.
A literature search was performed to return all publications relating to the PRESERFLO MicroShunt, which were then reviewed to extract information or guidance on patient selection, pre-operative patient preparation, peri-operative practices and techniques, and post-operative management. Alongside the literature search findings, participants in an expert panel meeting discussed their current practices relating to these same four aspects of PRESERFLO MicroShunt use.
PRESERFLO MicroShunt can be considered for the majority of patients with medically uncontrolled open-angle glaucoma, as well as in patients with uveitic glaucoma, advanced glaucoma and high myopia, adults with congenital glaucoma, and in some cases normal tension glaucoma patients. Prior to surgery, steroid drops may be given for 2-4 weeks if feasible, and acetazolamide may also be useful in patients with advanced glaucoma and high IOP. During surgery, a deep (8 mm) and wide sub-Tenon pocket is essential to surgical success. Mitomycin C is generally used at a concentration of 0.4 mg/mL for a minimum of 2-3 min. Intracameral bevacizumab and/or dexamethasone may be considered to increase the chance of surgical success. Post-operatively, antibiotics should be given for 7 days and steroid drops for 3-6 months. Monitoring visits may be less frequent than in patients undergoing trabeculectomy.
Management practices and surgical techniques for ab externo SBD vary, and surgeons must use their best clinical judgement based on the requirements of the individual patient. However, here we provide some recommendations for patient selection and pre-, peri- and post-surgical management based on the opinions of experts in the use of PRESERFLO MicroShunt, which we hope will prove useful in optimizing surgical outcomes.
结膜下滤过泡形成装置(SBD)比微创青光眼手术(MIGS)能更大程度地降低眼压,同时其侵入性低于传统手术技术。然而,管理实践和手术技术的差异表明,需要针对不同患者群体对这些手术提供简洁明了的指导。在此,我们根据对当前文献的回顾以及20位国际青光眼专家的意见,描述关于使用PRESERFLO微型分流器(一种外路SBD)的当前建议。
进行文献检索以获取所有与PRESERFLO微型分流器相关的出版物,然后对其进行审查,以提取有关患者选择、术前患者准备、围手术期实践和技术以及术后管理的信息或指导。除了文献检索结果外,专家小组会议的参与者讨论了他们在PRESERFLO微型分流器使用的这四个相同方面的当前做法。
对于大多数药物治疗无法控制的开角型青光眼患者、葡萄膜炎性青光眼患者、晚期青光眼患者、高度近视患者、先天性青光眼成年患者以及某些情况下的正常眼压性青光眼患者,均可考虑使用PRESERFLO微型分流器。手术前,如果可行,可给予类固醇滴眼液2 - 4周,乙酰唑胺对晚期青光眼和高眼压患者也可能有用。手术过程中,一个深(8毫米)且宽的颞下Tenon囊袋对手术成功至关重要。丝裂霉素C一般以0.4毫克/毫升的浓度使用至少2 - 3分钟。可考虑前房内注射贝伐单抗和/或地塞米松以增加手术成功的机会。术后,应给予抗生素7天,类固醇滴眼液3 - 6个月。随访次数可能比接受小梁切除术的患者少。
外路SBD的管理实践和手术技术各不相同,外科医生必须根据个体患者的需求运用最佳临床判断力。然而,在此我们根据PRESERFLO微型分流器使用专家的意见,提供一些关于患者选择以及手术前、手术中和手术后管理的建议,我们希望这些建议将有助于优化手术效果。